We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2013 by AB Science.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01872598
First Posted: June 7, 2013
Last Update Posted: June 7, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AB Science
June 5, 2013
June 7, 2013
June 7, 2013
January 2012
December 2015   (Final data collection date for primary outcome measure)
  • Cognition and Memory assessment [ Time Frame: Week 24 ]
    Effect on cognition and memory assessed by Alzheimer's disease Assessment Scale (ADAS-Cog)
  • Self-care and daily activities assesment [ Time Frame: Week 24 ]
    Effect on self-care and activities of daily living assessed by Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
A Multicenter, Double-blind, Placebo-controlled, Randomised, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
The objective is to compare the efficacy and safety of oral masitinib 3 or 4.5 mg/kg/day in combination with cholinesterase inhibitors and/or memantine to placebo in combination with cholinesterase inhibitors and/or memantine in patients with mild-to-moderate Alzheimer's disease.
Actual standard treatment for mild to moderately severe Alzheimer's dementia includes acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and a NMDA receptor antagonist (memantine for moderate to severe Alzheimer's disease). These medications have shown to have an effect on some cognitive and non cognitive symptoms of the pathology. However, their efficacy remains limited and may decrease with time. There is an unmet medical need in this pathology. Based on pre-clinical and clinical studies, masitinib (AB1010) can be considered as a good candidate at the dose of 3 and 4.5 mg/kg/day.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Alzheimer Disease
  • Drug: Group 1
    Other Name: Masitinib 3 mg/kg/day
  • Drug: Group 2
    Other Name: Masitinib 4.5 mg/kg/day
  • Drug: Group 3
    Other Name: Placebo 3 or 4.5 mg/kg/day
  • Experimental: Group 1
    Masitinib 3mg/kg/day
    Intervention: Drug: Group 1
  • Experimental: Group 2
    Masitinib 4.5mg/kg/day
    Intervention: Drug: Group 2
  • Placebo Comparator: Group 3
    Placebo 3 mg or 4.5mg/kg/day
    Intervention: Drug: Group 3
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
396
December 2016
December 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female patient
  2. Age ≥ 50 years, weighing more than 49,9 kg and with a Body Mass Index (BMI) >18
  3. Patient and/ or caregiver able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months
  4. Menopause ≥ 2 years for female patient
  5. Patient with dementia of Alzheimer's type, according to DSM-IV criteria
  6. Patient with probable Alzheimer' disease according to NINCDS-ADRDA criteria
  7. MMSE ≥ 12 and ≤ 25 at baseline
  8. Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (rivastigmine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at baseline, with no changes foreseen in therapy throughout the study
  9. Patient with adequate organ function at screening and baseline:

    • Absolute Neutrophils Count (ANC) ≥ 2 x 109/L
    • Hemoglobin ≥ 10 g/dL
    • Platelets (PTL) ≥ 100 x 109/L
    • AST/ALT ≤ 2.5 ULN
    • Bilirubin ≤ 1.5 ULN
    • Albuminemia > 1 x LLN
    • Urea ≤ 1.5 x ULN
    • Creatinin clearance > 60 mL/min (Cockcroft and Gault formula)
    • Proteinuria < 30 mg/dL on dipstick; in case of the proteinuria ≥ 30mg/dL, 24 hours proteinuria < 1.5g/24 hours
  10. Patient with a regular and reliable caregiver. The designated caregiver must be sufficiently familiar with the patient (as determined by the investigator) to provide accurate data. The caregiver must have regular contact with the patient (i.e., an average of 10 or more hours per week), must be able to observe for possible adverse events, must be able to oversee patient's compliance with the study treatment and to report on the patient's status and must be able to accompany the patient to all visits
  11. Patient, identified caregiver and, if applicable, patient surrogate able and willing to comply with study visits and procedures per protocol, understand, sign, and date the informed consent form at the screening visit prior to any protocol-specific procedures performed
  12. Male patient must agree to use one method of medically acceptable forms of contraception (his partner must also use one if she is of child-bearing potential) during the study and for 3 months after the last treatment intake.

Exclusion Criteria:

  1. Patient with any other cause of dementia not due to Alzheimer's disease, based on specific examination including a brain neuro-imagery exam within the last 6 months:

    • Other central nervous condition causing progressive deficits in memory and cognition, e.g. cerebrovascular disease (patient with not more than 4 microbleeds and not more than 2 lacunes at the MRI could be enrolled in the study), Parkinson's disease, Huntington's disease, brain tumor…
    • Systemic conditions known to cause dementia, e.g., hypothyroidism, untreated vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, HIV infection…
    • Substance-induced dementia
  2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients with light and mild forms of delusions and delirium will be allowed in the study
  3. Patient treated with any registered or putative cognitive/memory enhancer or disease modifier other than rivastigmine or memantine. (Patients taking Ginkgo Biloba can be enrolled providing it has been taken at a stable dose for at least 6 months
  4. Patient with evidence of psychosis and/or use of antipsychotic drugs at screening, or history of significant psychiatric disorder
  5. Patient with active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster), fungal, mycobacterium, protozoan, or other infection
  6. Patient with history of infection requiring hospitalization within 2 weeks of screening
  7. Patient presenting with cardiac disorders defined by at least one of the following conditions:

    • Patient with recent cardiac history (within 6 months) of:

      • Acute coronary syndrome
      • Acute heart failure (class III or IV of the NYHA classification)
      • Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
    • Patient with cardiac failure class III or IV of the NYHA classification
    • Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
    • Syncope without known aetiology within 3 months
    • Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
  8. Patient with chronic diarrhea
  9. Patient presenting with oedemas
  10. Patient with co existing dermatological disease (e.g. eczema, psoriasis) or history of skin allergy
  11. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
  12. Patient with life expectancy < 1 year

    Previous medications:

  13. Patient treated with any investigational agent within 4 weeks of screening
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT01872598
AB09004
Yes
Not Provided
Not Provided
AB Science
AB Science
Not Provided
Principal Investigator: Bruno DUBOIS, M.D., Ph.D. Pitié-Salpétrière
AB Science
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP